Galectin-3 plays an important role in fibroblast activation and fibrosis in animal models. Elevated galectin-3 levels are associated with poor long-term survival in heart failure (HF). We examined the relation between plasma galectin-3 levels and myocardial indices of systolic HF. We measured plasma galectin-3 in 133 chronic HF and 45 advanced decompensated HF subjects with echocardiographic and hemodynamic evaluation. In our chronic HF cohort, median plasma galectin-3 level was 13.9ng/mL [interquartile range: 12.1-16.9ng/mL]. Higher galectin-3 was associated with more advanced age (r=0.22, p=0.010) and poor renal function (estimated glomerular filtration rate [eGFR]: r= −0.24, p=0.007; cystatin C: r= 0.38, p<0.0001), and predicted all-cause mortality (Hazard ratio [HR] 1.86 [95% confidence interval: 1.36-2.54], p<0.001). In multivariate analysis, galectin-3 remained an independent predictor of all-cause mortality after adjusting for age, eGFR, left ventricular (LV) ejection fraction (EF), and mitral E/ septal Ea (HR 1.94 [1.30-2.91], p=0.001). However, galectin-3 did not predict the combined endpoint of all-cause mortality, cardiac transplantation, or HF hospitalization (p>0.05). Furthermore, there were no relations between galectin-3 and LV end-diastolic volume index (r= −0.05, p=0.61), LVEF (r= 0.10, p=0.25), or LV diastolic function (mitral E/septal Ea: r= 0.06, p=0.52; left atrial volume index: r= 0.08, p=0.41). In our advanced decompensated HF cohort, we did not observe any relation between galectin-3 and echocardiographic or hemodynamic indices. In conclusion, high plasma galectin-3 levels were associated with renal insufficiency and poorer survival in patients with chronic systolic HF. However, we did not observe a relation between galectin-3 and echocardiographic or hemodynamic indices.
Introduction
Increasing evidence has implicated galectin-3 in the pathogenesis and progression of heart failure (HF). In animal models, galectin-3 has been demonstrated to be robustly expressed in the failing heart and linked to myocardial fibrosis and remodeling [1] [2] [3] [4] in addition to renal fibrosis 5 . Intra-pericardial infusion of recombinant galectin-3 in healthy rats triggers inflammation involving macrophage and mast cell infiltration, cardiac interstitial and perivascular fibrosis, hypertrophy, and left ventricular systolic and diastolic dysfunction 1, 4 . In chronic stable and acute decompensated HF patients, elevated plasma galectin-3 levels have been linked to renal dysfunction and increased all-cause mortality risk [6] [7] [8] , and within the chronic HF setting, serum galectin-3 levels have been demonstrated to correlate with serum markers of cardiac extracellular matrix turnover 9 . Hence there is direct implication that galectin-3 is a mediator in the development of cardiac hypertrophy and fibrosis, and a potential biomarker for HF. Herein, we examine the relation between galectin-3 levels and echocardiographic indices of cardiac structure and function in patients with chronic stable HF, as well as echocardiographic and hemodynamic indices of cardiac structure and function in patients with advanced decompensated systolic HF.
Methods
We investigated the role of galectin-3 in human systolic HF in two separate cohorts. This study was approved by the Cleveland Clinic Institutional Review Board, and all subjects gave informed consent. In our chronic systolic HF cohort, we studied 133 patients enrolled in the Assessment of Doppler Echocardiography Prognosis and Therapy study, a singlecenter, prospective cohort study examining the natural history of stable but symptomatic chronic systolic HF patients with careful echocardiographic and biochemical phenotyping. Subjects enrolled were 18 to 75 years of age, had a diagnosis of HF for at least 3 months, a left ventricular (LV) ejection fraction (EF) ≤35% at the time of enrollment, New York Heart Association (NYHA) functional class I-IV symptoms, and were free of significant renal, hepatic, and valvular diseases 10 . Estimated glomerular filtration rate (eGFR) was calculated using the standard 4-variable Modification of Diet in Renal Disease equation 11 . Subjects were followed prospectively by telephone follow-up and chart review for heart failure hospitalizations and adverse events, with all-cause mortality data confirmed by Social Security Death Index up to 5 years of follow-up. In our advanced decompensated HF cohort, we measured plasma galectin-3 levels in 45 patients with advanced HF admitted to the HF intensive care unit with hemodynamic assessment and monitoring at the Cleveland Clinic for intensive medical therapy including vasoactive drugs. Subjects were 18 years of age or older, had an LVEF ≤35% for at least 6 months, elevated filling pressures defined by a pulmonary capillary wedge pressure >18 mmHg and/or a central venous pressure >8 mmHg. Exclusion criteria included mechanical ventilation, renal replacement therapy, post-cardiac transplantation and post tricuspid valve surgery.
In both studies, patients underwent comprehensive echocardiographic evaluation of cardiac structure as well as systolic and diastolic performance by an experienced research sonographer at the time of blood sample collection. Comprehensive transthoracic echocardiography was performed using commercially available HDI 5000 (Phillips Medical Systems, N.A., Bothell, Washington) and Acuson Sequoia (Siemens Medical Solutions USA Inc., Malvern, Pennsylvania) machines for our chronic systolic HF cohort and commercially available Vingmed, System Seven (General Electric Healthcare, USA) machine for our advanced decompensated systolic HF cohort. Two-dimensional and color Doppler imaging was performed in standard parasternal and apical views. Diastolic indices (including pulsewave Doppler, color M-mode, and tissue Doppler imaging) were acquired over ten consecutive beats using sweep speeds of 50 and 100 cm/s using previously described techniques and diastolic staging 10, 12 . The LVEF and cardiac volumes were measured using Simpson's biplane method. LV mass was calculated according to previously published recommendations 13 . All ventricular volume and mass measurements were indexed to body surface area. Measurements were averaged over three cycles (five cycles for atrial fibrillation).
All samples were collected into ethylenediaminetetraacetic acid plasma vacuum collecting tubes on ice simultaneously at the time of echocardiography and hemodynamic evaluation by delegated research personnel. Plasma was immediately separated, processed, and preserved in aliquots at −80°C until analysis. Plasma galectin-3 levels were determined by a commercially available sandwich enzyme-linked immunosorbent assay kit (Cat. No. BMS279/2, Bender MedSystems GmbH, Vienna, Austria) according to the manufacturer's protocol. A 2-fold dilution was utilized to bring concentrations within the measuring range of the assay 0.39-25ng/mL. Intra-assay and inter-assay coefficients of variation were <5%. Plasma cystatin C levels were determined by the N Latex cystatin C assay (Dade-Behring, Deerfield IL), a latex-enhanced nephelmetric immunoassay using rabbit polyclonal antibodies. The measuring range was 0.25-7.90 mg/L. Intra-assay and inter-assay coefficients of variation were < 1.8%. Recovery was 92.4-101.3% and the values were comparable between serum and plasma 14 . Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were assayed using a commercially available assay (Roche Elecsys® proBNP assay, Roche Diagnostics, Indianapolis IN). All laboratory analyses were performed by investigators blinded to clinical outcomes.
Continuous variables were summarized as mean ± standard deviation if normally distributed, and as median and interquartile range if non-normally distributed. Normality was assessed by the Shapiro-Wilk W test. Spearman's rank correlation method was used as a nonparametric measure of association between continuous plasma galectin-3 levels and clinical and echocardiographic indices. The Wilcoxon rank-sum or Kruskal-Wallis test were used to compare differences in continuous plasma galectin-3 levels across categorical clinical or echocardiographic indices. The Cox proportional hazards model was used to assess the clinical risk associated with increasing continuous standardized increments of natural logarithm-transformed plasma galectin-3 levels. The optimal receiver operating characteristic curve cut-off value for prediction of adverse clinical events was chosen as the value maximizing sensitivity plus specificity. The proportional hazards assumption was verified with log (time) vs. log[-log(survival)] plots. Kaplan-Meier survival plots were calculated from baseline to time of all-cause mortality. All p-values reported are from twosided tests and a p-value <0.05 was considered statistically significant. Statistical analyses were performed using JMP 8.0.2 and SAS 9.0 (SAS Institute, Cary, NC).
Results
In our chronic HF cohort, the mean and median plasma galectin-3 levels were 14.8 ± 4.0ng/ mL and 13.9 [interquartile range (IQR) 12.1-16.9]ng/mL, respectively (Table 1) . Higher plasma galectin-3 levels were associated with advanced age (Spearman's r=0.22, p=0.010), poor renal function (eGFR: r= −0.24, p=0.007; cystatin C: r=0.38, p<0.0001) ( (Table 1) . Again, higher plasma galectin-3 levels demonstrated even stronger association with poor renal function (eGFR: r= −0.39, p=0.024; cystatin C: r= 0.40, p=0.006) ( Table 2 ) and with ischemic etiology (p=0.013), but were not associated with age (p=0.65), NYHA functional class (p=0.54), gender (p=0.64), diabetic status (p=0.07), or beta-blocker or spironolactone use (p>0.10 for both).
In our chronic HF cohort, there was no correlation between plasma galectin-3 levels and indices of LV structure, including indexed LV mass or LV end-systolic or end-diastolic volume (p>0.48 for both), indices of left or right ventricular systolic function, including LVEF or right ventricular systolic wave (p>0.25 for both), or indices of LV diastolic function, including ratio of the mitral inflow early wave to the early diastolic myocardial relaxation velocity at septal mitral annulus, pulmonary vein systolic/diastolic ratio, or left atrial volume index (p>0.41 for all, Table 2 ). Furthermore, plasma galectin-3 levels did not correlate indices of right ventricular function including semi-quantitative right ventricular systolic function severity. There was weak correlation between galectin-3 and NT pro-BNP that reached marginal significance (r=0.18, p=0.053) ( Table 2 ). In our advanced decompensated HF cohort, plasma galectin-3 levels were not associated with indices of LV structure (p>0.46 for all), LVEF or indices of LV diastolic dysfunction or right ventricular function (p>0.32 for all, Table 2 ). Also, plasma galectin-3 was not associated with any hemodynamic measures measured by pulmonary artery catheter, including pulmonary capillary wedge pressure (p=0.45) and cardiac index (p=0.70), as well as pulmonary artery mean pressure (p=0.99) and central venous pressure (p=0.76).
We have up to 5-year long-term follow-up of our chronic HF cohort, which demonstrated that higher galectin-3 levels were associated with higher all-cause mortality, particularly in those with elevated cystatin C levels (Table 3, Figure 1 ). In multivariate analysis, galectin-3 remained an independent predictor of mortality after adjusting for age, eGFR, LVEF, and ratio of the mitral inflow early wave to the early diastolic myocardial relaxation velocity at septal mitral annulus (Table 3) . Galectin-3 also predicted mortality independent of age and cardiac structure, or age and cystatin C levels in this cohort (Table 3 ). However, galectin-3 did not predict the composite endpoint of all-cause mortality, cardiac transplantation, or HF hospitalization (p=0.34).
Discussion
The major findings of this study include: 1) the lack of a strong relation between galectin-3 and echocardiographic measurements of cardiac structure and function in chronic stable systolic HF, and between galectin-3 and invasive hemodynamic measurements in advanced decompensated HF; and 2) the relatively stronger relation between galectin-3 and indices of renal dysfunction including cystatin C levels. Taken together, these data emphasize that galectin-3 is a pleotropic molecule mediating immune response, inflammation, and fibrogenesis rather than specific to cardiac (or renal) performance alone.
Galectin-3 is a macrophage-derived mediator, which can activate fibroblasts and induce their proliferation and collagen deposition 1, 5, 15 . In pre-clinical studies, increased expression of galectin-3 is associated with subsequent development of cardiac dysfunction 1 . Several human studies have indicated that elevated levels of galectin-3 provide independent prognostic value in HF. In the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, higher galectin-3 levels measured by the same research assay were associated with poorer survival at 1-year follow-up in 209 subjects with a diagnosis of acute decompensated heart failure seen at the Emergency Department, as well as at 4-year follow-up in a subset of patients 6, 16 . In the Deventer-Alkmaar heart failure study (DEAL-HF), 232 elderly subjects with advanced symptoms from chronic HF were followed for 6.5 years, and elevated galectin-3 was also found to be a significant predictor of mortality risk even following adjustment for age, eGFR, and NT-proBNP (hazard ratio 1.24, 95% confidence interval 1.03-1.50, p=0.026) 8 . The results within our chronic systolic HF cohort corroborate those from DEAL-HF, with higher plasma galectin-3 levels predicting increased risk of all-cause mortality. In contrast, we found a lack of relation between plasma galectin-3 levels and some of the strongest cardiac-specific echocardiographic or hemodynamic predictors of poor survival in systolic HF. The lack of any clear association with cardiac-specific indices in our study is surprising considering the fact that cardiac fibrosis is an important component of myocardial stiffness, and our findings are discrepant with prior reports. In the echocardiographic subset of the PRIDE study, where 76 subjects with acute decompensated HF and 39 non-HF patients underwent echocardiographic evaluation between 23-73 hours after hospital contact, galectin-3 levels were modestly associated with early diastolic myocardial relaxation velocity at mitral annulus (r=−0.246, p=0.03) and ratio of the mitral inflow early wave to early diastolic myocardial relaxation velocity at mitral annulus (r=0.345, p=0.01), as well as tricuspid and mitral regurgitation that was not seen in our cohort. It is important to recognize that the patient population in the PRIDE study was very different from our studies, with a mean LVEF 45.5±15%, a mean LV end-diastolic volume of 109±44ml, and a mean ratio of the mitral inflow early wave to early diastolic myocardial relaxation velocity at mitral annulus of 12.3±6 in the acute HF cohort (n=76) 16 . Only 15% of subjects in PRIDE admitted for acute decompensated HF had history of cardiomyopathy. In comparison, our study populations consisted of more advanced systolic HF (mean LVEF 26 and 28%, mean LV end-diastolic volume of 218 and 231ml, and mean ratio of the mitral inflow early wave to early diastolic myocardial relaxation velocity at mitral annulus of 15.5 and 20.3 in our chronic and acute systolic HF cohorts, respectively for acute and chronic HF), with echocardiographic measurements performed at the time of blood draw. Different assays used between different studies may also affect the findings, even though all the studies to date showed consistency in demonstrating relations between galectin-3 with renal function and all-cause mortality. Nevertheless, the mere differences in baseline echocardiographic characteristics may potentially explain the marked differences in the observations regarding the relationships between galectin-3 and cardiac structure and function.
While this discrepancy requires confirmation in future human studies, we hypothesize a few potential explanations. First, not all diastolic dysfunction in chronic systolic HF can be explained by myocardial fibrosis. In fact, extensive remodeling with cardiac enlargement inevitably causes myocyte stretch and altered relaxation as a result of myocardial deformities. Other non-fibrotic contributors of diastolic dysfunction include ischemia, altered energetics, and even disruption of normal calcium homeostasis. In addition, there may be a disassociation between tissue and circulating galectin-3 levels such that systemic levels of galectin-3 may not reflect the myocardial expression and consequences of galectin-3. An alternative explanation for our observation of a discrepancy between the ability of galectin-3 to predict risk without clear association with cardiac structure and function may lie in the relatively stronger relation between galectin-3 levels and renal function. This relation observed in our study is consistent with prior reports. In both PRIDE and DEAL-HF study, there was a strong inverse relation between galectin-3 levels and eGFR 8, 16 . Interestingly, a recent report from the same investigators of DEAL-HF identified stronger prognostic value within subgroup of patients with HF and preserved ejection fraction, who may be more dependent on renal insufficiency as contributor of congestive symptoms 17 . Indeed, galectin-3 expression and secretion has been linked to the development of renal fibrosis in animal models 5 . In an experimental glomerulonephritis model, galectin-3 has been shown to modulate renal mesangial cell proliferation and led to alterations in extracellular matrix 18 . The availability of cystatin C measurements in our cohort, which demonstrated a strong correlation with galectin-3, further illustrated the tight association between circulating galectin-3 levels and renal insufficiency. It is interesting to note that cystatin C itself is a cysteine protease inhibitor endogenously and ubiquitously produced in all nucleated cells, which has been associated with alterations in extracellular matrix production 9, 19, 20 and the presence of left ventricular hypertrophy in non-heart failure subjects 21, 22 . It is therefore conceivable that the pathophysiologic role of galectin-3 leading to progressive renal compromise may be more prominent than its impact on cardiac pathology, and such an association with renal impairment may in part determine galectin-3's prognostic role in heart failure. Further investigations regarding the clinical utility of galectin-3 are warranted. aminoterminal pro-B-type natriuretic peptide [NT-proBNP] = 1.36 pg/mL; 1 standard deviation for left ventricular ejection fraction = 6.4%; 1 standard deviation for ratio of the mitral inflow E wave to the early diastolic myocardial relaxation velocity at septal mitral annulus = 12; 1 standard deviation for left ventricular end-systolic volume index = 30 mL/m2; 1 standard deviation for left ventricular end-diastolic volume index = 34 mL/m2; 1 standard deviation for cystatin C = 0.94 mg/L).
